Lincoln Pharmaceuticals Ltd - 531633 - Reg 40 (10) PCS Certificate On Transfer/Transmission/Transposition For The Half Year Ended March 31, 2021.
With reference to the above cited subject, please find enclose herewith Half Yearly Compliance Certificate for the Period Ended on March 31, 2021 as required to be sent under Regulation 40 (9) of SEBI (Listing and Obligations Requirements) Regulations, 2015. LINCOLN PHARMACEUTICALS LTD. - 531633 - Reg. 7(3) - Compliance Certificate For The Half Year Ended March 31, 2021.
We enclose herewith certificate duly signed by the Company Secretary & Compliance Officer of the Company and the Authorized Representative of Registrar & Share Transfer Agent i.e. M/s. Link Intime India Private Limited, Category-I with the Securities and Exchange Board of India vide Registration Number: INR000004058 as required under Regulation 7 (3) of SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015 for the Half Year Ended on March 31, 2021. Lincoln Pharmaceuticals Ltd - 531633 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to provision of Regulation 74 (5) of the SEBI (Depositories and Participants) Regulations, 2018, we hereby submit the confirmation certificate as received from M/s. Link Intime India Private Limited, RTA for the Quarter Ended March 31, 2021. LINCOLN PHARMACEUTICALS LTD. - 531633 - Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- NIREN DESAIDesignation :- Company Secretary and Compliance Officer Lincoln Pharmaceuticals Ltd - 531633 - Shareholding for the Period Ended March 31, 2021
Lincoln Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here
Lincoln Pharmaceuticals promoters increase stake to 37.25% in FY-21
Plan to hike their holding further LINCOLN PHARMACEUTICALS LTD. - 531633 - Closure of Trading Window
Intimation of Closure of Trading Window during the F.Y. 2021-2022. LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find enclosed a Media Release titled 'Promoters of Lincoln Pharma increases promoter group holding by 4.9% during FY 20-21 to 37.25%.' Lincoln Pharmaceuticals Ltd - 531633 - Intimation Of Order Passed By Hon''ble NCLT For Dissolution Of Company''s Wholly Owned Subsidiary.
With reference to above captioned subject, we would like to inform you that, the Company has received an order passed by Hon''ble NCL T for dissolution of M/s. Savebux Enterprises Private Limited (a Wholly Owned Subsidiary)of the Company on March 26, 2021 under Section 59 of the Insolvency and bankruptcy Code. 2016. Accordingly the said Company stands dissolved w:e.f. March 03, 2021 i.e. the date of passing of the order. Lincoln Pharmaceuticals Ltd - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Munjal Mahendrabhai Patel